Abstract: The composition and methodology associated with the formulation of a halogenated phosphonic acid labeled in the ring moiety are disclosed having the formula: ##STR1## wherein R.sub.1 is aryl and is labeled with a halogen and R.sub.2 is hydrogen, alkyl, alkenyl, amino, benzyl, hydroxyl--CH.sub.2 PO.sub.3 H --CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2 and is labeled with halogen. The compositions are especially useful for scanning investigations of in vivo deposits of calcium.

Abstract: Body fluids are assayed for aryloxypropylamine beta-adrenergic antagonists and/or their active metabolites by agglutination reaction with antibody for the antagonist and/or active metabolite. The antibody is produced from an antigen comprising a conjugate of an immunogenic protein linked by a diazo moiety to an aryloxypropylamine beta-adrenergic antagonist.

Abstract: Healing of a wound is accelerated by administering a new form of nerve growth factor having a molecular weight of about 116,000 and which is stable in dilute aqueous solutions. The nerve growth factor is obtained from mouse submandibular gland or mouse saliva. An extract of mouse submandibular gland or mouse saliva is subjected to ion-exchange chromatography to recover a component of the gland or saliva rich in the nerve growth factor and containing proteinaceous material which does not degrade the nerve growth factor. The pure nerve growth factor is obtained by subjecting the component rich in nerve growth factor to at least one additional chromatography step, usually two to four, to recover pure nerve growth factor having a molecular weight of about 116,000. The nerve growth factor is applied directly to the wound.

Abstract: Cell lines for producing monoclonal antibodies to hepatitis virus are established by immunizing animal lymphocytes with hepatitis antigen to form antibody producing cells which then are fused with myeloma cells. The resultant somatic cell hybrids can be cloned. These clones produce monoclonal antibodies to individual antigenic determinates unique to hepatitis virus.

Abstract: A blood pressure reducing composition which inhibits renin in vivo which composition has the peptide structureZ-His-Pro-Phe-His-X-X-Val-Tyr-Ywherein the xs are the same or different and are phenylalanine, a chlorinated phenylalanine or tyrosine, Y is a charged amino acid and Z is proline or polyproline having up to 5 prolyl residues.